NVET Insider Trading Activity and SEC Form 4 Filings
NVET insider trading summary
No open-market insider purchases or sales of Nexvet Biopharma plc (NVET) have been reported on SEC Form 4 in the past 12 months.
Latest NVET insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 4, 2016 | David Gearing | Chief Scientific Officer | Buy | $30K (9,000 @ $3.35) |
| Mar 3, 2016 | Geraldine T Farrell | VP Operations, General Counsel | Sell | $432 (132 @ $3.27) |
| Mar 3, 2016 | David Gearing | Chief Scientific Officer | Buy | $7K (2,113 @ $3.26) |
| Mar 2, 2016 | Ashraf Hanna | Director | Buy | $5K (1,500 @ $3.20) |
| Feb 26, 2016 | Michael B. Fisch | 10% Owner | Buy | $10K (3,007 @ $3.36) |
| Feb 26, 2016 | David T Kim | 10% Owner | Buy | $10K (3,007 @ $3.36) |
| Feb 26, 2016 | Thomas G. Roberts Jr. | 10% Owner | Buy | $10K (3,007 @ $3.36) |
| Feb 26, 2016 | Andrew J M Spokes | 10% Owner | Buy | $10K (3,007 @ $3.36) |
| Feb 26, 2016 | Daniel J. Hirsch | 10% Owner | Buy | $10K (3,007 @ $3.36) |
| Feb 26, 2016 | Farallon Partners L L C/Ca | 10% Owner | Buy | $10K (3,007 @ $3.36) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.